Initial and sustained cardiovascular risk reduction in a pharmacist-led diabetes cardiovascular risk clinic

British Journal of Diabetes and Vascular Disease

Volumn 8, Issue 1, 2008, Pages 34-38

  McGowan, Neil ^a   Cockburn, Alison ^a   Strachan, Mark W J ^a   Padfield, Paul L ^a   McKnight, John A ^a  

^a WESTERN GENERAL HOSPITAL   (United Kingdom)

Author keywords

Cardiovascular risk; Diabetes; Hypertension

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; ATENOLOL; BENDROFLUMETHIAZIDE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; CHOLESTEROL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOXAZOSIN; FUROSEMIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IRBESARTAN; LIPID; LISINOPRIL; NIFEDIPINE;

ARTICLE; BLOOD PRESSURE MONITORING; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CONSULTATION; DIABETES MELLITUS; DRUG DOSE INCREASE; DRUG DOSE REGIMEN; DRUG DOSE TITRATION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FOLLOW UP; HOSPITAL DISCHARGE; HUMAN; HYPERTENSION; KIDNEY DISEASE; LIFESTYLE MODIFICATION; LONG TERM CARE; MAJOR CLINICAL STUDY; PHARMACIST; RISK REDUCTION; STATISTICAL SIGNIFICANCE;

EID: 41349120768     PISSN: 14746514     EISSN: None     Source Type: Journal    
DOI: 10.1177/14746514080080010801     Document Type: Article

References (15)

1. Huxley R, Barzi F, Woodward M. Excess risk of fatal coronary heart disease associated with diabetes in men and women: meta-analysis of 37 prospective cohort studies. BMJ 2006;332:73-8.
2. Booth GL, Kapral MK, Fung K, Tu JV. Relation between age and cardiovascular disease in men and women with diabetes compared with non-diabetic people: a population based retrospective cohort study. Lancet 2006;368:29-35.
3. Turner R, Holman R, Stratton I et al. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes:UKPDS 38. BMJ 1998;317:703-12.
4. Hansson L, Zanchetti A, Carruthers SG et al. Effects of intensive blood-pressure lowering and low dose aspirin in patients with hypertension: Principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998;351:1755-62.
5. Collins R, Armitage J, Parish S, Sleigh O, Petro R. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003;361:2005-16.
6. Colhoun HM, Betteridge DJ, Durrington PN et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controllled trial. Lancet 2004; 364:685-96.
7. Eliasson B, Cederholm J, Nilsson P, Gudbjonsdottir S. The gap between guidelines and reality: Type 2 diabetes in a national diabetes register 1996-2003. Diabet Med 2005;22:1420-26.
8. Graede P, Vedel P, Larsen N et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003;348:343-94.
9. Donnan PT, MacDonald TM, Morris AD. Adherence to prescribed oral hypoglycaemic medication in a population of patients with type 2 diabetes: A retrospective cohort study. Diabet Med 2002; 19:279-84.
10. Halpern MT, Khan ZM, Schmier JK et al. Recommendations for evaluating compliance and persistence with hypertension therapy using retrospective data. Hypertension 2006;47:1039-48.
11. Pickering TG, Hall JE, Appel LJ et al. Recommendations for Blood Pressure measurement in Human and experimental animals: Part 1: Blood pressure measurement in Humans: A statement for professionals from the subcommittee of professional and public education of the American Heart Association council on high blood pressure research. Circulation 2005;111:697-716.
12. Williams B, Poulter NR, Brown MJ et al. Guidelines for the management of hypertension. Report of the fourth working party of the British Society of hypertension. J Hum Hypertens 2004; 18:139-85.
13. Dawes MG, Coats AJ, Juszczak E. Daytime ambulatory blood pressure is better at predicting mortality than clinic blood pressure. Blood Press Monit 2006;11:111-18.
14. Dolan E, Stanton A, Thijs L et al. Superiority of ambulatory over clinic blood pressure measurement in predicting mortality: the Dublin outcome study. Hypertension 2005;46:156-61.
15. Lowey A, Moore S, Norris C, Wright D, Silcock J, Hammond P. The cost effectiveness of pharmacist-led treatment of cardiac risk in type 2 diabetes. Pharm World Sci 2007 March 30 - EPUB ahead of print.